The Food and Drug Administration announced its decision in July, in letters to CBD makers Charlotte’s Web of Colorado and Irwin Naturals of California. The companies sought agency clearance to market their products as a new dietary ingredient.
The FDA pointed to two reasons for the rejections:
- CBD is the active ingredient in a pharmaceutical drug and therefore should not be available over the counter.
- Insufficient data about CBD safety and efficacy.